XAIR
$0.81
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform.
Intraday
Recent News
Beyond Air Inc (XAIR) Expands Focus on Nitric Oxide Therapies
Beyond Air Inc (NASDAQ:XAIR) is among the best NASDAQ penny stocks to buy according to analysts. On February 20, Beyond Air Inc (NASDAQ:XAIR) commented that it was pleased with a review article that recognized the potential of high-dose nitric oxide as a potential therapy for respiratory illnesses. The peer-reviewed article appeared in a journal of […]
How The Narrative On Beyond Air (XAIR) Is Resetting Around LungFit PH And Delayed Approval
The consensus fair value estimate for Beyond Air has shifted from US$12.33 to US$8.67, signaling a reset in how analysts are framing potential upside. Bulls point to the second generation LungFit PH system and a clearer, though extended, regulatory path as reasons they still see room for upside. Bears, on the other hand, view the lower targets as reflecting a longer and more uncertain route to meaningful sales. As you read on, you will see how these differing views are shaping the evolving...
Beyond Air Inc (XAIR) Q3 2026 Earnings Call Highlights: Impressive Revenue Growth and Strategic ...
Beyond Air Inc (XAIR) reports a 105% revenue increase and significant cost reductions, while navigating ongoing financial challenges and FDA approval processes.
Beyond Air, Inc. Q3 2026 Earnings Call Summary
Moby summary of Beyond Air, Inc.'s Q3 2026 earnings call
Top Midday Decliners
TryHard (THH) unveiled on Wednesday an equity purchase agreement in which Summer Explorer Investment